Catalent Expands Capabilities At German Facility
Eric Schmidhaeuser, managing director of Schorndorf operation, said: “We believe the addition of this new potent handling and over-encapsulation area will help to meet the needs of our
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).